![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article 
Journal of Clinical Microbiology, November 2007, p. 3828-3829, Vol. 45, No. 11
0095-1137/07/$08.00+0 doi:10.1128/JCM.01590-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Menzies School of Health Research, Charles Darwin University, Darwin Northern Territory, Australia Northern Territory Clinical School, Flinders University, Darwin Northern Territory, Australia Department of Primary Industries and Fisheries, Townsville, Queensland, Australia Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, St. Mary's Hospital, London, United Kingdom Health Protection Agency, Plymouth, Devon, United Kingdom Centre for Infections, Health Protection Agency, London, United Kingdom
Received 10 August 2007/ Accepted 13 August 2007
 |
ABSTRACT |
|---|
 Top ABSTRACT TEXTREFERENCES |
|---|
|
TEXT |
|---|
|
TopABSTRACTTEXTREFERENCES |
|---|
Multilocus sequence typing (MLST) has been used to clarify the genetic relationships of B. pseudomallei isolates from different locations (3). MLST initially showed that isolates of B. pseudomallei from Thailand and those from northern Australia were distinct (2, 7). However, a recent study comparing a historical B. pseudomallei collection from Southeast Asia to that of the MLST database (http://bpseudomallei.mlst.net/) concluded that Australian isolates may not be distinct from those of Thailand (4). This conclusion was based on the finding that MLST ST60 was common to environmental isolates from both countries. The authors stated that this finding was profoundly significant to melioidosis epidemiology and research, since the prior finding that Australian B. pseudomallei isolates were distinct from other isolates sourced elsewhere was no longer the case.
We have now tracked down the Australian B. pseudomallei ST60 isolates and show that the results are a case of mistaken identity. Furthermore, we confirm that to date, all known Australian B. pseudomallei STs are indeed distinct from all known Thai STs. The incorrect attribution of a strain to a specific geographic location or clinical finding can have major ramifications, and the scenario we describe illustrates how critical it is to ensure the accuracy of strain data deposited in publicly accessible data sets such as the MLST databases.
The five "Australian" ST60 isolates used in the recent study (4) were all listed in the MLST database as being from environmental sources. Three had been obtained for MLST in the laboratory of B.G.S. from the large B. pseudomallei collection at the Central Public Health Laboratory, United Kingdom, and two had been obtained by the Centers for Disease Control (CDC), United States. We established, through the curator of the MLST database (D.G.), that the two CDC isolates were actually the same as two strains from the United Kingdom, having been part of a collection sent to the CDC from the United Kingdom. Indeed, it is now recognized that there was some duplication in the B. pseudomallei MLST database as a result of the same strains being deposited separately in the United Kingdom and in the U.S. collections with different identifiers (data not shown).
Having established that there were only three "Australian" ST60 strains, we then ascertained their histories. These three strains had been cultured by A.D.T. in 1983 from soil from a single property in southeast Queensland, Australia, as part of an investigation into an outbreak of melioidosis in pigs. These isolates, D228, D260, and D304, were sent to D.A.D. in the United Kingdom in 1992. Testing by both A.D.T. and D.A.D., including testing by an API 20NE kit (bioMerieux, Paris, France), the lack of agglutination with B. pseudomallei antisera and the lack of virulence in guinea pigs had confirmed that these three were not B. pseudomallei isolates, although they had not been identified to a species level.
We have now been able to retrieve and reculture two of these 1983 strains from A.D.T.'s long-term collection; stored D228 was nonviable. Both D260 and D304 are clearly not B. pseudomallei strains. They are oxidase-positive gram-negative bacilli that cannot be identified to a species level with both an API 20NE and an API 20E (bioMerieux, Paris, France) kit. They are agglutination negative with B. pseudomallei antisera and are negative with the B. pseudomallei-specific type III secretion system PCR (5). Furthermore, MLST confirmed they were not B. pseudomallei strains and were completely different than the ST60 strain. Only four of the seven MLST loci were able to be sequenced using the normal MLST primers, and the allelic sequences obtained (which were identical for both D260 and D304) were very divergent from any allele in the MLST database.
It is now evident that there was a strain identity mixup when the "Australian" ST60 strains were incorporated into the United Kingdom collection and were included in the original MLST study (3). What were thought to be the "Australian" ST60 strains were presumably ST60 strains from another source. While the real identities of the strains typed as ST60 remain speculative, it is likely that they were isolates from Thailand, since Thai isolates make up the vast majority of the isolates in the United Kingdom collection. ST60 is one of the more common STs found in Thailand (7).
Two other STs have been attributed to both Australia and Southeast Asia in the past. There were two "Australian" ST23 isolates listed in the database that we have found to also be United Kingdom and CDC duplicates of a single isolate from the same collection sent by A.D.T. to D.A.D. in 1992. The original isolate, X1003, was isolated by A.D.T. in 1978 from a goat in Townsville, Queensland. We have retrieved and recultured this isolate and found it belongs to a novel ST of B. pseudomallei, ST517, not ST23, confirming that another isolate substitution error is likely to have occurred. Another "Australian" isolate, typed as ST84, was cultured from a patient with an uncertain travel history, and as discussed by McCombie et al., this isolate was likely from an infection acquired in Southeast Asia (4).
The misidentified isolates have been removed from the MLST website database. At present, there are 178 STs from Australia and 224 STs from Thailand represented in the database, and there is complete separation of Australian and Thai STs among those isolates whose origins are verifiable from original sources. B. pseudomallei strain collections in laboratories in regions of nonendemicity often contain a mixture of isolates from travelers to regions of endemicity who present with melioidosis, isolates obtained from other collections, and isolates from laboratories in regions of endemicity. Because of the implications of errors such as those described here, we call for a system of provenance to document the identity, the associated clinical information, and the chain of custody of isolates in global databases.
|
ACKNOWLEDGMENTS |
|---|
This work is supported by a grant from the Australian National Health and Medical Research Council, and B.G.S. acknowledges funding from the Wellcome Trust.
|
FOOTNOTES |
|---|
Published ahead of print on 26 September 2007.
|
REFERENCES |
|---|
|
TopABSTRACTTEXTREFERENCES |
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|
